Pharmaceuticals, Biotechnology & Life Sciences

Vericel insider trades reveal a disciplined buy‑sell‑exercise pattern, boosting confidence in the COO’s long‑term belief in the company’s regenerative‑medicine growth.

Altimmune insider buying surges as CEO‑elect Pisano Wayne buys 5,000 shares near a 52‑week low, backing the company’s FDA Breakthrough Therapy designation and promising clinical‑stage growth.

Vertex insider sells 4,500 shares in routine plan‑based trade; market stays bullish on VRTX’s pipeline and earnings outlook.

CEO sells 5,466 Monte Rosa shares at $23.88: liquidity or confidence? Insider trades reveal no major downside, but highlight ongoing capital‑raising plans.

MoonLake CFO’s zero‑cost purchase of 354k restricted shares signals strong insider confidence amid a 2,800% social‑media buzz and an upcoming FDA‑approved BLA, hinting at potential upside for long‑term investors.

Insider confidence fuels bullish outlook for Mettler‑Toledo: CEO buys boost, stable holdings, and strong growth signals.

Insider buying at Nkarta signals confidence in its biotech pipeline—President Mahmood Nadir and execs are staking options on a $2.74 peak, hinting at future upside.

Zoetis insider buying signals leadership confidence and hints at future growth opportunities in animal‑health markets.

Insider buying fuels optimism for Erasca, as Garner Ebun buys shares under a Rule 10b5‑1 plan and exercises options, showing confidence in the company’s oncology pipeline and potential upside.

Insider sales at Puma Biotechnology spike amid modest price rise—does this signal confidence or caution? Explore the insider moves, market sentiment, and what it means for investors.